Epizyme, Inc.ย incurred loss of 29 cents per share in the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of loss of 49 cents and the year-ago loss of 52 cents.
a developer of therapeutics for the treatment of patients with genetically defined cancers
Industry Biotechnology